The new formulation of the 0,05% sodium hypochlorite electrolytic solution for cutaneous use: reasons and advantages

AboutOpen

View Publication Info
 
 
Field Value
 
Title The new formulation of the 0,05% sodium hypochlorite electrolytic solution for cutaneous use: reasons and advantages
 
Creator Scalise, Alessandro
 
Subject Antiseptics
Efficacy
Skin lesions
Sodium hypochlorite
Tolerability
 
Description Superinfection of skin lesions is quite common, and often delays wound recovery. Infection control plays therefore a key role in the management of skin lesions, requiring the use of specific antimicrobials. Among available agents, topic antiseptic drugs are currently recommended as a first-choice option, to be preferred to antibiotics, given the growing resistance to these drugs. Compared to antibiotics, antiseptic drugs have a wider spectrum of action, including bacteria, fungi, virus, protozoa, and prions. The ideal antiseptic for the management of an infected skin lesion is expected to be both highly effective and well tolerated, in order to promote the physiologic process of tissue restoration. Among available antiseptics, the 0,05% sodium hypochlorite electrolytic solution meets these criteria: the product proved to be effective in vitro and in animal experimental models against a wide range of microorganisms, besides exerting an anti-inflammatory action in the absence of any irritating, cytotoxic or carcinogenic adverse effect, and being useful in biofilm removal. Similarly, in several clinical trials, the 0,05% sodium hypochlorite electrolytic solution was demonstrated to be very effective and safe in the management of infected skin wounds: based on these results, this product should be strongly considered among the first-choice options for the disinfection of skin wounds. The new formulation, developed according to the latest reference standards for wound healing and in agreement with current guidelines, is qualitatively improved, with an expected positive impact in every field of clinical application and a subsequent benefit for treated patients.
 
Publisher AboutScience srl - Piazza Duca d'Aosta 12 - 20124 Milano MI (Italy)
 
Date 2021-03-22
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Review article
 
Format application/pdf
application/epub+zip
text/html
 
Identifier https://journals.aboutscience.eu/index.php/aboutopen/article/view/2221
10.33393/ao.2021.2221
 
Source AboutOpen; Vol. 8 No. 1 (2021): January-December 2021; 14-22
AboutOpen; V. 8 N. 1 (2021): January-December 2021; 14-22
2465-2628
 
Language eng
 
Relation https://journals.aboutscience.eu/index.php/aboutopen/article/view/2221/2295
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2221/2296
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2221/2297
 
Rights Copyright (c) 2021 The Authors
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library